
    <html>
    <head><title>ACB.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> ACB.TO  <span style='color:orange; font-weight:800; margin-left:8px;'>nan</span>
        <span style='font-weight:normal; font-size: 18px;'>(41d - quarterly earnings)</span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/ACB.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  — </span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-11-18</td><td>0.30</td><td></td><td>quarterly results</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news highlights "strong Q1 results" and "extended profit momentum," indicating that the quarterly results exceeded expectations. This aligns with the "quarterly or annual results" event, warranting a score of +0.2 to +0.4. The phrasing "continued financial improvement" suggests a positive outlook, further supporting a slightly positive score. The overall impact is moderately positive, but not overwhelmingly so, hence the score of 0.3. --- <br> - Tilray Brands reported strong Q1 results, extending its profit momentum. Investors may find this positive news encouraging, suggesting continued financial improvement. <br><br>*** REZUMAT *** - Tilray Brands reported strong Q1 results. - Profit momentum has been extended. - Focus on financial improvement.   (gemma3:12b-it-q4_K_M on 2025-11-18 22:10:05)</td><td><a href='https://finance.yahoo.com/news/tilray-brands-extends-profit-momentum-134600035.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-10</td><td>0.30</td><td></td><td>quarterly results</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Breakdown: quarterly or annual results: Anticipates positive quarterly cash flow - This suggests a potential improvement and aligns with a positive outlook, scoring +0.2. surge in medical sales globally: This is a positive product launch/market expansion, scoring +0.1. monitoring future performance: This cautionary note reduces the overall impact slightly, but doesn't significantly detract from the positive news. The "Yahoo's brand family" and "uses cookies" are promotional and irrelevant to the financial outlook, so they receive a score of 0. --- <br> - Aurora Cannabis reports a surge in medical sales globally and anticipates positive quarterly cash flow. This positive update suggests a potential turnaround for the company, though investors should monitor future performance closely. <br><br>*** REZUMAT *** - Aurora Cannabis: Medical sales are booming worldwide. - Anticipates positive quarterly cash flow. - Part of Yahoo's brand family. - Uses cookies for website functionality and analytics. - Investors should monitor future performance.   (gemma3:12b-it-q4_K_M on 2025-11-13 09:46:07)</td><td><a href='https://finance.yahoo.com/news/aurora-cannabis-medical-sales-boom-132517943.html' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-11-07</td><td>0.40</td><td></td><td>nan</td><td>0.4 local feel              __   ACB.TO __    -> i:0.4<-                      <br><br>FEELING: total score 0.4 --- <br> - Consider buying ACB and TSLA for growth; avoid UPS and PLTR due to revenue decline and overvaluation. <br><br>*** REZUMAT *** - ACB upgraded: high‑margin medical cannabis sales, record Adjusted EBITDA. - TSLA upgraded: software subscriptions, energy solutions, strong EV market position. - UPS downgraded: declining revenues, trade issues. - PLTR downgraded: overvaluation, declining cash flow margins.   (gpt-oss:20b on 2025-11-08 22:52:57)</td><td><a href='https://seekingalpha.com/news/4518609-sa-analyst-upgradesdowngrades-tsla-acb-ups-pltr' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-11-06</td><td>-0.30</td><td></td><td>quarterly earnings</td><td>-0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score -0.3 --- <br> - Aurora Cannabis shows strong revenue and margin growth, positive EBITDA, and a debt‑free balance sheet, but the Q2 earnings miss signals earnings volatility. Investors should weigh the upside from expanding medical cannabis markets against the risk of earnings swings. <br><br>*** REZUMAT *** - Q2 2026 EPS -$0.65 vs expectation $0.03; revenue up 11% to $90M. - Global medical cannabis revenue +15%; international revenue +22%. - Adjusted gross margin 61% (+700bps), exceeding 60% target. - Adjusted EBITDA +52% to $15M, from -$58M to +$15M over 5 years. - No debt, strong cash position, GMP‑certified facilities in Canada & Germany. - Market leader in Germany, Australia, Poland, UK; 1B AUD market in Australia. - Germany imports up 72t (2024), projected >double in 2025; GMP certification extended 3 years. - Poland market doubled to 5t; high‑potency cultivars launched, 80–90% market share. - Positive EBITDA trend, no debt, but EPS miss signals earnings volatility.   (gpt-oss:20b on 2025-11-07 11:23:11)</td><td><a href='https://www.insidermonkey.com/blog/aurora-cannabis-inc-nasdaqacb-q2-2026-earnings-call-transcript-1641115/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-06</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 --- <br> - EPS beat expectations but negative margins and ROE signal ongoing losses; institutional buying hints upside, yet analyst sentiment remains mixed—invest cautiously. <br><br>*** REZUMAT *** - EPS $0.09 vs $0.03 consensus, beat by $0.06. - Negative ROE –1.49%, net margin –5.66%. - Stock $4.46, down 1.8%, volume 1.67M vs avg 1.84M. - Market cap $250.7M, P/E –23.47, beta 1.71. - 50‑day SMA $5.25, 200‑day SMA $5.01. - 52‑week low $3.42, high $6.91. - Quick ratio 1.51, current ratio 2.97, debt‑to‑equity 0.06. - Institutional holdings up: Tidal +6%, Goldman +4.1%, Jones +9,615.6%, Wyoming +10.5%. - Analyst ratings: moderate buy, 2 strong buys, 1 buy, 1 hold, 2 sells.   (gpt-oss:20b on 2025-11-07 11:27:32)</td><td><a href='https://www.marketbeat.com/instant-alerts/aurora-cannabis-nasdaqacb-announces-quarterly-earnings-results-2025-11-05/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-05</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news highlights a "strong Q2" with a "significant 52% EBITDA growth." This directly relates to quarterly results. A 52% growth is above expectations, warranting a score of +0.3. The phrase "positive trend" suggests continued positive performance, reinforcing the positive sentiment. The call to "monitor if this momentum continues" indicates a degree of caution, preventing a higher score. --- <br> - Aurora Cannabis reported a strong Q2 with a significant 52% EBITDA growth, signaling a positive trend for the company. Investors should monitor if this momentum continues. <br><br>*** REZUMAT *** - ACB reports strong Q2 results. - EBITDA grew by 52%. - Positive trend for the company.   (gemma3:12b-it-q4_K_M on 2025-11-05 23:40:49)</td><td><a href='https://www.gurufocus.com/news/3185795/aurora-cannabis-acb-reports-strong-q2-results-with-52-ebitda-growth' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-05</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: quarterly or annual results: The news reports "record Q2 2026 revenue" and "Adjusted EBITDA increased 52%". This indicates results exceeding expectations, contributing a score of +0.3. analyst meetings: The mention of an analyst rating ("Hold" with a price target) and a TipRanks AI Analyst rating receives a low score, as it's a standard element of news reports. cash position: The company maintains a "strong cash position" and is "debt-free," which is a positive sign, but the impact is relatively minor. profitability challenges: The mention of "profitability challenges" and a "Strong Sell" technical sentiment signal slightly reduces the overall score, but the positive revenue and EBITDA growth outweigh this. --- <br> - Aurora Cannabis reported record Q2 2026 revenue driven by medical cannabis sales and improved margins. While facing profitability challenges and a bearish technical outlook, the company maintains a strong cash position and focuses on high-margin markets. <br><br>*** REZUMAT *** - ACB reports record Q2 2026 global medical cannabis net revenue: $70.5 million. - International medical cannabis revenue up 22%: $42.7 million. - Adjusted EBITDA increased 52%: $15.4 million. - Cash on hand: $141.9 million, debt-free cannabis business. - Analyst rating: Hold with C$7.00 price target. - TipRanks AI Analyst: Neutral rating due to profitability challenges. - Market Cap: C$362.4M. - Technical Sentiment Signal: Strong Sell.   (gemma3:12b-it-q4_K_M on 2025-11-06 00:08:13)</td><td><a href='https://www.tipranks.com/news/company-announcements/aurora-cannabis-achieves-record-revenue-in-q2-2026' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-05</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news highlights "strong Q2 2026 results" with "significant revenue and adjusted EBITDA growth." This aligns with the "quarterly or annual results" event. Specifically, the adjusted EBITDA growth of 52% is a positive signal. I'm assigning a score of +0.3 to reflect this positive performance, leaning towards the lower end of the positive range due to the need to monitor if the trend continues. The mention of share price is irrelevant to the financial assessment. --- <br> - Aurora Cannabis reported strong Q2 2026 results with significant revenue and adjusted EBITDA growth, indicating positive momentum. Investors should monitor if this trend continues. <br><br>*** REZUMAT *** - Aurora Cannabis: Q2 2026 results announced. - Global Medical Cannabis Net Revenue: $70.5 million (YoY 15% increase). - International Medical Cannabis Net Revenue: $42.7 million (22% increase). - Adjusted EBITDA: $15.4 million (52% growth). - ACB shares: Trading at $6.42.   (gemma3:12b-it-q4_K_M on 2025-11-06 00:14:28)</td><td><a href='https://www.theglobeandmail.com/investing/markets/stocks/ACB-T/pressreleases/35922714/stocks-in-play-aurora-cannabis-inc/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-05</td><td>0.20</td><td></td><td>quarterly earnings</td><td>0.2 local feel              __   ACB.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news indicates that Aurora Cannabis exceeded Q2 revenue estimates, specifically driven by higher medical cannabis sales. This falls under quarterly or annual results above expectations, which warrants a score of +0.2. The mention of "potential for continued growth" suggests a positive outlook, reinforcing this score. The cautionary note about "future results and market conditions" prevents a higher score, as it introduces uncertainty. The source (Proactive Investors) and author (Sean Mason) are irrelevant to the financial assessment. --- <br> - Aurora Cannabis exceeded Q2 revenue estimates, driven by higher medical cannabis sales. This positive performance suggests potential for continued growth in the medical sector, but investors should monitor future results and market conditions. <br><br>*** REZUMAT *** - Aurora Cannabis Q2 revenue exceeded estimates. - Higher medical cannabis sales fueled the positive result. - Proactive Investors published the news. - Sean Mason, Senior Journalist, authored the report.   (gemma3:12b-it-q4_K_M on 2025-11-06 00:16:13)</td><td><a href='https://ca.proactiveinvestors.com/companies/news/1081876/aurora-cannabis-q2-revenue-tops-estimates-on-higher-medical-cannabis-sales-1081876.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-05</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news explicitly states that Aurora Cannabis exceeded Q2 earnings and revenue expectations. This falls under the "quarterly or annual results" event. Exceeding expectations warrants a positive score. Given the lack of specific numerical data and the cautious wording ("potential positive trend," "monitor future performance"), the score is moderate (+0.3) rather than the higher end of the range. --- <br> - Aurora Cannabis exceeded Q2 earnings and revenue expectations, signaling a potential positive trend for the company. Investors should monitor future performance to confirm this momentum. <br><br>*** REZUMAT *** - Aurora Cannabis (ACB) reported Q2 earnings and revenue above estimates. - Specific numerical results are not provided in the text. - News pertains to financial performance exceeding expectations.   (gemma3:12b-it-q4_K_M on 2025-11-06 00:17:33)</td><td><a href='https://finance.yahoo.com/news/aurora-cannabis-inc-acb-tops-142501894.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-04</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Breakdown: quarterly or annual results: The mention of Q2 2026 earnings expected on Nov 5, with revenue around C$63M, is a forward-looking statement. While not explicitly above/below expectations, it's a key event. (0) guidance updates: The expectation of revenue around C$63M can be considered a form of guidance. (0) FDA or Canada Health decisions: The potential U.S. rescheduling is a significant event with potential to remove tax burdens and enable listings. This is a positive catalyst. (+0.4) accretive to DCF per share: The potential U.S. rescheduling could positively impact DCF per share. (+0.3) stock splits: (0) buyback programs: (0) analyst meetings: (0) regulatory changes: The potential U.S. rescheduling is a regulatory change that could be beneficial. (+0.2) strategic partnerships or joint ventures: (0) promotional language and backward-looking data: The YTD and YoY stock performance data are backward-looking and receive a very low score. (0) Note: The positive impact of the potential U.S. rescheduling is the most significant factor driving the positive score. --- <br> - Aurora Cannabis shows promise with its focus on the higher-margin medical cannabis segment and international expansion. While regulatory changes in the U.S. could be a catalyst, investors should monitor the upcoming earnings report and overall market conditions. <br><br>*** REZUMAT *** - ACB.TO trades at C$6.85 (TSX) / US$5.00 (NYSE) as of Nov 4, 2025, with a C$390M market cap. - Stock up 1020% YTD in 2025, but down 24% YoY. - Rally triggered by Trump's CBD endorsement and potential U.S. rescheduling. - Medical cannabis sales up 37% to C$65M, representing ~66% of revenue. - Adjusted EBITDA positive at C$11M, with free cash flow over C$9M. - Q2 2026 earnings expected on Nov 5, revenue around C$63M. - Aurora faces competition from Tilray and Canopy Growth. - Recreational cannabis sales declined 20% due to oversupply. - Expanding medical cannabis production in Germany via facility upgrades. - Potential U.S. rescheduling could remove tax burdens and enable listings.   (gemma3:12b-it-q4_K_M on 2025-11-05 00:19:08)</td><td><a href='https://ts2.tech/en/aurora-cannabis-acb-to-stock-soars-on-cbd-buzz-in-depth-analysis-2025-outlook/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-28</td><td>0.20</td><td></td><td>Strategic partnerships or joint ventures</td><td>0.2 local feel              __   ACB.TO __    -> i:0.4<-                     **   ** 2025-10-31 **   <br><br>** 2025-10-31  Strategic partnerships or joint ventures ***<br>FEELING: total score 0.2 Reasoning: The news describes a strategic partnership between Grubhub and Instacart. This falls under the "strategic partnerships or joint ventures" event. The description highlights potential synergy – expanding Grubhub's offerings and attracting more customers. While the news doesn't explicitly state accretion to DCF or EPS, the potential for increased customer base and Grubhub+ subscriptions suggests a positive, albeit moderate, impact. Therefore, a score of +0.2 is assigned, leaning towards the higher end of the 0 to +0.3 range for partnerships with clear synergy. The mention of monitoring customer adoption and profitability indicates some uncertainty, preventing a higher score. --- <br> - This partnership between Grubhub and Instacart is a positive development, expanding Grubhub's offerings and potentially attracting more customers. The integration of grocery delivery could boost Grubhub+ subscriptions and overall platform usage. Investors should monitor customer adoption and the impact on profitability. <br><br>*** REZUMAT *** - Grubhub partners with Instacart to offer grocery delivery on its platform. - Partnership launches today, nationwide availability by end of October. - Grubhub customers can order from over 1,000 grocery retailers via Instacart. - Grubhub has 20 million customers and access to 415,000 restaurants. - Instacart partners with over 1,800 retailers across North America. - Grubhub+ members get $0 delivery fees on $25+ grocery orders. - All customers get 30% off up to three grocery orders ($75+) for 3 months.   (gemma3:12b-it-q4_K_M on 2025-10-28 23:28:02)</td><td><a href='https://investingnews.com/c-o-r-r-e-c-t-i-o-n-grubhub/' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-10-27</td><td>-0.35</td><td></td><td>quarterly earnings</td><td>-0.35 local feel              __   ACB.TO __    -> i:0.35<-                      <br><br>FEELING: total score -0.35 Breakdown: quarterly or annual results: Missed earnings estimates (-0.2). analyst meetings: Sell ratings reiterated and downgrades (-0.1). institutional buying: While present, it's not enough to offset the negative sentiment, so a minimal positive impact (0.05). backward-looking data: The 1-year low/high, price-to-earnings ratio, and return on equity are all backward-looking and receive a very low score. Expected EPS: The expected EPS for the current fiscal year is a slightly positive signal, but overshadowed by the missed earnings and overall negative sentiment (0.05). --- <br> - Aurora Cannabis faces continued negative sentiment with reiterated Sell ratings and missed earnings. While institutional buying exists, the stock's fundamentals remain weak, suggesting caution for investors. <br><br>*** REZUMAT *** - Weiss Ratings reaffirmed a Sell (D-) rating on Aurora Cannabis (ACB). - Zacks Research upgraded from Strong Sell to Hold on October 6th. - Wall Street Zen downgraded from Hold to Sell on July 18th. - ACB opened at $5.25 on Friday. - Market cap: $295.16 million. - Price-to-earnings ratio: -27.63. - 1-year low: $3.42, 1-year high: $6.91. - Qly earnings: ($0.19) EPS, revenue $71.98M (missed estimates). - Return on equity: -1.49%, net margin: -5.66%. - Expected EPS for current fiscal year: $0.46. - Several institutions recently bought shares (DKM, JW, Headlands, Engineers Gate, Silver Oak). - Institutional ownership: 47.63% of stock.   (gemma3:12b-it-q4_K_M on 2025-10-27 21:26:38)</td><td><a href='https://www.defenseworld.net/2025/10/27/aurora-cannabis-acb-sell-d-rating-reiterated-at-weiss-ratings.html' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    